<DOC>
	<DOC>NCT01136863</DOC>
	<brief_summary>FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized, placebo-controlled,parallel-group trial. The primary objective is to compare the long-term effects on the incidence of fatal and non-fatal stroke (and secondarily of other cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5 mg once a day) or of a placebo, in hypertensive patients whose blood pressure had preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg once a day) to be continued in association with felodipine or placebo, throughout the trial.</brief_summary>
	<brief_title>Felodipine Event Reduction Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Felodipine</mesh_term>
	<criteria>SBP of 210 mmHg or less and DBP less than 115 mmHg if under antihypertensive treatment; SBP 160210 mmHg or DBP 95115 mmHg if untreated. Presence of at least one or two risk factors or cardiovascular diseases Informed consent obtained stroke or myocardial infarction during the previous 6 months; secondary hypertension; unstable angina; cardiomyopathy or significant valvular disease; serum creatinine greater than 178 mmol/l (2.0 mg/dl); gout; uncontrolled diabetes(fasting plasma glucose &gt; 10 mmol/l, 180 mg/dl despite therapy); serious pulmonary or hepatic disease; known contraindications to study drugs; unwillingness to cooperate</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>hypertension</keyword>
	<keyword>felodipine</keyword>
	<keyword>moderate to high risk patients</keyword>
</DOC>